Advanced Prostate Cancer VL

Exploring PSMA Expression Variations in Metastatic Prostate Cancer: The Role of Reversible Epigenetic Changes - Michael Haffner

Details
Michael Haffner and Andrea Miyahira discuss a JCI Insight publication, "Reversible Epigenetic Alterations Mediate PSMA Expression Heterogeneity in Advanced Metastatic Prostate Cancer". The study investigated PSMA expression heterogeneity in advanced metastatic prostate cancer, finding that the expression pattern of PSMA varies significantly between different metastatic sites and patients. They als...

EMBARK Trial Shows Promising Results for High-Risk Prostate Cancer Treatment, Enzalutamide's Impact on Metastasis-Free Survival - Neal Shore

Details
Neal Shore discusses the EMBARK trial with Alicia Morgans. The study investigated whether enzalutamide plus leuprolide treatment or enzalutamide monotherapy could prolong metastasis-free survival compared with placebo plus leuprolide for men with high-risk biochemical relapse. The study's primary endpoint was met, with patients in the combination arm showing a 58% reduction in the risk of metastas...

Improving Genetic Testing Rates in Advanced Prostate Cancer - Pedro Barata

Details
Pedro Barata speaks with Alicia Morgans about his presentations focusing on genetic and germline testing in patients with advanced prostate cancer. Dr. Barata highlights a study that found more than two-thirds of the patient population had not been tested for homologous recombination repair (HRR) mutations, and another analysis of over 8,100 patients with metastatic castration-resistant prostate c...

DLL3 Targeting Bispecifics: A New Hope for Tough-to-Treat Prostate Cancer Patients - Rahul Aggarwal

Details
Alicia Morgans hosts a discussion with Rahul Aggarwal about his ongoing research on DLL3 targeting BiTE therapy. DLL3 is expressed in an aggressive form of prostate cancer known as neuroendocrine prostate cancer. Dr. Aggarwal's study focuses on using an immunotherapeutic approach to target DLL3, using a compound developed by Amgen that enhances immune response. With 40 patients already enrolled in...

Treating Biochemical Recurrence With Enhanced Therapy Added to Standard of Care and Targeted Radiation Using PET Imaging, ECOG-ACRIN EA8191 (INDICATE) - Neha Vapiwala

Details
In this conversation, Neha Vapiwala joins Alicia Morgans in a conversation on the ECOG-ACRIN EA8191 (INDICATE) phase III trial in progress. In patients with prostate cancer who experience biochemical recurrence, the ECOG-ACRIN EA8191 (INDICATE) trial examines whether patients without PET-detected lesions outside the pelvis benefit from the addition of apalutamide to standard salvage radiotherapy +...

NCCN Guidelines: A Framework for PET Imaging Integration in Prostate Cancer Care - Edward Schaeffer

Details
In this collaborative discussion, Alicia Morgans and Edward (Ted) Schaeffer examine the evolving guidelines for integrating PET imaging into the diagnosis and treatment of prostate cancer. Dr. Schaeffer emphasizes that these NCCN guidelines, which frequently adapt to new medical developments, act as a flexible framework rather than a rigid rulebook. The conversation explores the application of PSM...

SPARE Trial's Implications for Prostate Cancer Patients - Carsten-Henning Ohlmann

Details
Alicia Morgans and Carsten-Henning Ohlmann discuss the SPARE trial, an exploratory phase two study involving chemo-naive metastatic castration-resistant prostate cancer patients. The trial compares the standard of care - ADT (Androgen Deprivation Therapy) plus abiraterone plus prednisone, versus abiraterone plus prednisone without the continuation of ADT. Preliminary results show no significant di...

Unveiling the Clinical Potential of ctDNA: Implications for Prostate Cancer Management - Neeraj Agarwal

Details
Neeraj Agarwal delves into two ground-breaking studies, discussing the importance of ctDNA testing and the clinical implications of SPOP mutations in patients with metastatic prostate cancer. The first study, led by Dr. Kim Chi, demonstrates that ctDNA testing is a viable alternative to invasive tissue testing, particularly in detecting BRCA and ATM mutations. CtDNA tests showed impressive sensiti...

Immune System Biology of Androgen and AR Functions in T cells in Prostate Cancer - Amy Moran

Details
Amy Moran joins Alicia Morgans in a discussion on the mechanisms of immunotherapy resistance in prostate cancer patients, and how androgens or the androgen receptor (AR) contribute. Amy Moran received a Prostate Cancer Foundation Young Investigator Award for this research which aims to reveal how androgens and AR activity regulate human T cell function and immunotherapy resistance and may reveal n...

Advances in Liquid Biopsies for Guiding Cancer Therapy - Jeffrey Ross

Details
Jeffrey Ross speaks about the evolution and application of liquid biopsies in cancer treatment, including in cases of advanced metastatic breast cancer and prostate cancer. Drawing from his experience with circulating cancer cells, he details the development of circulating DNA and emphasizes the importance of precision medicine and personalized care. He contrasts liquid biopsies with tissue biopsi...